TBPH Stock Recent News
TBPH LATEST HEADLINES
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?
Theravance's (TBPH) fourth-quarter earnings and revenues beat estimates. The company achieves profitability on an adjusted basis during the same time.
Theravance Biopharma, Inc. (TBPH) Q4 2023 Earnings Call Transcript
Theravance Biopharma (TBPH) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.21 per share a year ago.
The heavy selling pressure might have exhausted for Theravance Bio (TBPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Theravance Biopharma shares fell more than 20% after the company reported that its therapeutic for chronic obstructive pulmonary disease (COPD), a common lung disease, failed a clinical trial. Its stock was down 20.7% at US$9.14 before Friday's opening bell.
Theravance Biopharma Inc.'s stock TBPH, -0.60% tumbled 21% early Friday,ter the biotech said a Phase 4 trial of its Yupelri treatment for patients with severe to very severe Chronic Obstructive Pulmonary Disease, or COPD, failed to meet its main goal. The trial dubled PFIR-2 aimed to show greater improvement in lung function for Yupelri delivered by standard jet nebulizer compared to Spiriva delivered via a dry powder inhaler in adults with COPD.
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?
Thervance (TBPH) incurs a narrower-than-expected loss in the third quarter of 2023. Revenues marginally beat estimates.
Theravance Biopharma has a diversified portfolio in the healthcare sector, with the potential for high returns and risk mitigation. The company's financials have shown improvement, with increased revenue and reduced R&D costs. Theravance's products, YUPELRI and Ampreloxetine, show promise in treating COPD and MSA, but face challenges in terms of off-target effects and competition from established drugs.